Overtreatment and associated risk factors among multimorbid older patients with diabetes.
HbA1c
glucose-lowering medication
multimorbidity
polypharmacy
type 2 diabetes mellitus
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
21
04
2023
received:
09
10
2022
accepted:
16
05
2023
medline:
15
9
2023
pubmed:
8
6
2023
entrez:
7
6
2023
Statut:
ppublish
Résumé
In multimorbid older patients with type 2 diabetes mellitus (T2DM), the intensity of glucose-lowering medication (GLM) should be focused on attaining a suitable level of glycated hemoglobin (HbA In a secondary analysis of a multicenter study of multimorbid older patients, we evaluated HbA Among the 564 patients with T2DM (median age 78 years, 39% women), mean ± standard deviation HbA In this multicountry study of multimorbid older patients with T2DM, more than one third were overtreated, highlighting the high prevalence of this problem. Careful balancing of benefits and risks in the choice of GLM may improve patient care, especially in the context of comorbidities such as severe renal impairment, and frequent non-GP healthcare contacts.
Sections du résumé
BACKGROUND
In multimorbid older patients with type 2 diabetes mellitus (T2DM), the intensity of glucose-lowering medication (GLM) should be focused on attaining a suitable level of glycated hemoglobin (HbA
METHODS
In a secondary analysis of a multicenter study of multimorbid older patients, we evaluated HbA
RESULTS
Among the 564 patients with T2DM (median age 78 years, 39% women), mean ± standard deviation HbA
CONCLUSIONS
In this multicountry study of multimorbid older patients with T2DM, more than one third were overtreated, highlighting the high prevalence of this problem. Careful balancing of benefits and risks in the choice of GLM may improve patient care, especially in the context of comorbidities such as severe renal impairment, and frequent non-GP healthcare contacts.
Substances chimiques
Metformin
9100L32L2N
Hypoglycemic Agents
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2893-2901Subventions
Organisme : European Research Council
ID : 634238
Pays : International
Organisme : Swiss National Science Foundation
ID : SNSF 320030_188549
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : SNSF 325130_204361/1
Pays : Switzerland
Informations de copyright
© 2023 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
Références
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-1530.
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315(10):1034-1045.
American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 13. Older adults: standards of medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S195-S207.
American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus, Moreno G, Mangione CM, Kimbro L, Vaisberg E. Guidelines abstracted from the American Geriatrics Society guidelines for improving the Care of Older Adults with diabetes mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11):2020-2026.
American Geriatrics Society Choosing Wisely Workgroup. American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc. 2013;61(4):622-631.
American Geriatrics Society. Avoid using medications other than metformin to achieve hemoglobin A1c < 7.5% in most older adults; moderate control is generally better. Published February 21, 2013; revised April 23, 2015. Accessed 2 September 2022. https://www.choosingwisely.org/clinician-lists/american-geriatrics-society-medication-to-control-type-2-diabetes/
Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356-362.
Lega IC, Campitelli MA, Austin PC, et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia. 2021;64(5):1093-1102.
Mata-Cases M, Mauricio D, Real J, et al. Potential risk of overtreatment in patients with type 2 diabetes aged 75 years or older: data from a population database in Catalonia, Spain. J Clin Med. 2022;11(17):5134. doi:10.3390/jcm11175134.
Maciejewski ML, Mi X, Sussman J, et al. Overtreatment and deintensification of diabetic therapy among Medicare beneficiaries. J Gen Intern Med. 2018;33(1):34-41.
Blum MR, Sallevelt B, Spinewine A, et al. Optimizing therapy to prevent avoidable hospital admissions in multimorbid older adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585.
Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med. 2016;35(30):5730-5735.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Arnold SV, Lipska KJ, Wang J, Seman L, Mehta SN, Kosiborod M. Use of intensive glycemic Management in Older Adults with diabetes mellitus. J Am Geriatr Soc. 2018;66(6):1190-1194.
Hart HE, Rutten GE, Bontje KN, Vos RC. Overtreatment of older patients with type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2018;20(4):1066-1069.
Sussman JB, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175(12):1942-1949.
Christiaens A, Henrard S, Zerah L, Dalleur O, Bourdel-Marchasson I, Boland B. Individualisation of glycaemic management in older people with type 2 diabetes: a systematic review of clinical practice guidelines recommendations. Age Ageing. 2021;50(6):1935-1942.
Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA. 2011;306(24):2670-2672.
Adam L, Moutzouri E, Baumgartner C, et al. Rationale and design of OPtimising thERapy to prevent avoidable hospital admissions in multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open. 2019;9(6):e026769.
Sacks DB, John WG. Interpretation of hemoglobin A1c values. JAMA. 2014;311(22):2271-2272.
Khan SU, Khan MZ, Raghu Subramanian C, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. JAMA Netw Open. 2020;3(5):e205202.
Cowie CC, Casagrande SS, Geiss LS. Prevalence and incidence of type 2 diabetes and prediabetes. In: Cowie CC, Casagrande SS, Menke A, et al., eds. Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/pubmed/33651562; 2018.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
Frank C, Weir E. Deprescribing for older patients. CMAJ. 2014;186(18):1369-1376.
Kosjerina V, Carstensen B, Jørgensen ME, et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study. Lancet Healthy Longev. 2021;2(9):e561-e570.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.